许多疫苗正在临床开发和实施中,以预防2019年冠状病毒病(COVID-19)的严重病程和致命后果。本系统综述旨在总结和整合有关COVID-19疫苗皮肤副作用的研究结果。这项系统的审查是通过搜索PubMed的科学数据库进行的,Scopus,科学直接,和从COVID-19开始到2021年5月10日的网络知识。根据系统审查和荟萃分析的首选报告项目清单对文章进行审查和分析。在根据资格标准筛选搜索结果后,纳入了17项关于COVID-19疫苗皮肤副作用的研究。结果表明,最常见的注射部位反应和延迟大的局部反应,从所有疫苗类型中产生,发红/红斑(39%),其次是:瘙痒(28%),颈部荨麻疹(17%),上肢,和树干,泥状喷发(6.5%),玫瑰糠疹(3%),肿胀,燃烧,等等。大多数皮肤反应发生在女性(84%),中年人,在第一次接种疫苗后,发病范围为接种后1至21天。此外,皮肤反应通常是自限性的,几乎不需要治疗干预,这不被认为是注射第二剂的障碍。总之,严重的皮肤副作用非常罕见,批准的疫苗具有令人满意的安全性。因此,轻度或中度皮肤反应不应阻止人们接种疫苗。在某些人群中,例如有过敏症和局部注射反应史的患者,疫苗接种前的咨询和保证,使用适当的药物可能会有所帮助。然而,需要更多的研究来调查所有COVID-19疫苗的副作用。
Numerous vaccines are under clinical development and implementation for the prevention of severe course and lethal outcomes of coronavirus disease 2019 (COVID-19). This systematic review aims to summarize and integrated the findings of studies regarding cutaneous side effects of COVID-19 vaccines. This systematic review conducted by searching the scientific databases of PubMed, Scopus, Science direct, and Web of knowledge from the beginning of the COVID-19 to May 10, 2021. Articles were reviewed and analyzed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Seventeen studies on cutaneous side effects of COVID-19 vaccines were included after the screening of search results based on to the eligibility criteria. The results showed that the most common injection site reactions and delayed large local reactions, arising from all vaccine types, were redness/erythema (39%), followed by: itchiness (28%), urticarial rash (17%) on the neck, upper limbs, and trunk, morbilliform eruptions (6.5%), Pityriasis rosea (3%), swelling, and burning, and so forth. Most cutaneous reactions occurred in women (84%), and middle-aged people, after the first dose of vaccine, with the onset ranged from 1 to 21 days after vaccination. In addition, cutaneous reactions were generally self-limiting, and needed little or no therapeutic intervention, that were not regarded as a barrier to injecting a second dose. In conclusion, severe cutaneous side effects are very rare and approved vaccines have satisfactory safety profiles. Therefore, mild or moderate cutaneous reactions should not discourage people from vaccination. In certain groups such as patients with allergies and a history of local injection reactions, pre-vaccination counseling and assurance, also use of appropriate medications may be helpful. However, more studies are needed to investigate the side effect profile of all COVID-19 vaccines.